Director, Global Value and Health Economics, Outcomes Research

This is a fully remote position, open to applicants in California, +1 more state.

📋 Description

• Formulate and implement payer evidence strategies for both global and US markets in Oncology.

• Spearhead global HEOR initiatives and strategies in gastroesophageal adenocarcinoma while supporting a key Oncology asset’s clinical development pipeline.

• Integrate payer, HTA, and reimbursement considerations into Phase 2 and Phase 3 clinical development initiatives.

• Act as the US HEOR lead for commercial, Medicare Part B/D, and Medicaid access.

• Develop and author AMCP dossiers, US commercial/Medicare budget impact models, and state Medicaid submission packages.

• Equip US Payer Field Teams with interactive economic models, presentation materials, and digital resources.

• Track US health policy developments and create evidence roadmaps for IRA, CMS Drug Price Negotiation, Part D redesign, ICER reviews, and NCCN Evidence Blocks.

• Provide guidance on innovative payment models and value-based contracting.

• Design and implement health economic models, such as CEA, CUA, and BIM, throughout the product lifecycle.

• Oversee the architecture and validation of global core economic models.

• Lead the creation of global value dossiers, systematic literature reviews, global evidence libraries, ITCs, NMAs, and adaptations of economic models.

• Collaborate on studies related to real-world evidence, natural history, burden of illness, treatment patterns, and comparative effectiveness.

• Direct HEOR launch readiness, lifecycle management, label expansions, value defense, and post-launch evidence initiatives.

• Manage HEOR commitments within Integrated Evidence Generation Plans.

• Collaborate with Market Access, Brand Teams, Medical Affairs, Clinical Development, Regulatory, Commercial, and EU/INT HEOR teams.

• Lead the publication and presentation of findings at scientific and health economics congresses.

• Mentor junior scientists, cross-functional colleagues, and HEOR fellows.

• Ensure adherence to legal, regulatory, and corporate standards.

⛳️ Requirements

• A Master’s degree (MSc, MS, MPH, PhD) in Health Economics, Outcomes Research, Pharmacoeconomics, or a similar quantitative discipline.

• 7–10 years of experience in HEOR, Global Value, or Health Economics within the biopharmaceutical industry or at a leading HEOR consulting firm.

• Preferred experience with oncology assets.

• Proven track record in leading HEOR strategy and executing evidence deliverables for marketed, inline pharmaceutical products, including lifecycle management, label expansions, and value defense.

• Comprehensive understanding of US payers and population health decision-makers, particularly in Oncology Pathways.

• Experience managing regional trade-offs regarding evidence needs during the development of Phase 2/3 protocols.

• Served as launch lead for at least 2 assets as US HEOR lead or at the country-level HTA lead.

• Demonstrated success as a US HEOR lead or in driving US pre-launch HEOR deliverables, including AMCP PIE dossiers, US budget impact models, and payer field enablement.

• Experience in conducting post-marketing RWE, patient registry studies, and economic evaluations in rare diseases, specialized medicine, or complex chronic conditions.

• Experience collaborating with regional HEOR teams, such as EU/INT, on global HTA reassessments, renewals, or pricing renegotiations.

• Strong record of peer-reviewed publications in health economics and outcomes research.

• In-depth knowledge of US managed care archetypes and international HTA frameworks.

• Advanced skills in health economic modeling techniques, including Markov, partitioned survival, microsimulation, and discrete event simulation.

• Proven ability to partner with US Payer Field Teams to develop interactive economic models and value presentation tools.

• Practical expertise in rare disease/orphan drug access.

• Experience with launch readiness, lifecycle management, clinical trial design, policy, value assessments, matrix leadership, mentorship, project, budget, and vendor management.

• Familiarity with FDAMA Section 114, 21st Century Cures Act, EU JCA, NICE, G-BA, and CADTH.

🏝️ Benefits

• Discretionary annual cash bonus or incentive compensation.

• Discretionary equity grants through the Long Term Equity Incentive Plan.

• Medical insurance coverage.

• Dental insurance coverage.

• Vision insurance coverage.

• 401k retirement savings plan.

• Flexible paid vacation policy.